KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $1.3 billion.

  • Biomarin Pharmaceutical's Cash & Equivalents rose 85.08% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 85.08%. This contributed to the annual value of $942.8 million for FY2024, which is 24.86% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Cash & Equivalents is $1.3 billion, which was up 2.99% from $1.2 billion recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Cash & Equivalents high stood at $1.3 billion for Q3 2025, and its period low was $580.1 million during Q1 2023.
  • In the last 3 years, Biomarin Pharmaceutical's Cash & Equivalents had a median value of $785.4 million in 2023 and averaged $878.7 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Cash & Equivalents plummeted by 39.24% in 2021 and then skyrocketed by 85.08% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Cash & Equivalents (Quarterly) stood at $587.3 million in 2021, then rose by 23.37% to $724.5 million in 2022, then climbed by 4.22% to $755.1 million in 2023, then climbed by 24.86% to $942.8 million in 2024, then skyrocketed by 85.08% to $1.3 billion in 2025.
  • Its Cash & Equivalents stands at $1.3 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.0 billion for Q1 2025.